MedTrace Logo

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

NCT02676830 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-02-18

No results posted yet for this study

Summary

The purpose of this study is to Evaluation of absorption, metabolism, and excretion of \[14C\]-K-312 and estimation of the absolute bioavailability of K-312 in healthy male subjects

Conditions

Interventions

DRUG

K-312 100 mg

Single oral dose

DRUG

K-312 100 ug C14 IV

microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes

Sponsors & Collaborators

  • Kowa Research Institute, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-02-28
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02676830 on ClinicalTrials.gov